The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

including Johnson & Johnson and AstraZeneca. Cytokinetics is said to be holding out for between $130 to $145 a share, according to Betaville, citing sources familiar with the matter, but ...

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...